Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease
Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease